Shutdown Looms: Another FDA Merry-go-round Ride
This article was originally published in Scrip
The FDA has been on this merry-go-round before: If Congress doesn't act by Oct. 1 to pass a fiscal year 2016 budget – or at least a short-term or long-term continuing resolution (CR) – the federal government will shut down, which means the agency would be forced to close its doors, potentially stalling new drug and biologic applications and putting off other work vital to the biopharmaceutical industry.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.